Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine and Rituximab in Marginal Zone Lymphoma
NCT00117156Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2003
- Primary completion
- Oct 2008
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine and rituximab in marginal zone lymphoma (MZL), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Objective Response Rate. Started Dec 2003; status: completed.
02
Drugs
fludarabinerituximab
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT00117156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117156.